Novartis Unveils Long-Term Efficacy of Remibrutinib in Chronic Spontaneous Urticaria at EAACI Congress

(IN BRIEF) Novartis has presented new data at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress, showcasing the sustained efficacy and safety of remibrutinib, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in chronic spontaneous urticaria (CSU). Results … Read the full press release →